Breast cancer screening is back in the news because policy leaders and researchers are revisiting how mammograms should be recommended and covered. For most average-risk U.S. women, the practical advice has not changed: keep following current screening guidance and confirm your schedule with your clinician.
The FDA is pressing sponsors and researchers to report clinical trial results on time, saying missing data can distort what doctors and patients think they know. A new FDA push and an NIH policy update are raising the stakes for transparency as the clinical-trials system evolves.
The FDA’s May 15 approval adds two early-stage breast cancer uses for Enhertu, also known as fam-trastuzumab deruxtecan-nxki. The update matters for some adults with HER2-positive disease, but it does not change screening guidance or replace a discussion about surgery, chemotherapy, and other treatment options with an oncology team.
A new randomized clinical trial suggests centralized patient navigation can help people get a follow-up colonoscopy sooner after a positive FIT stool test. The finding matters because a FIT is a screening step, not the endpoint: an abnormal result still needs diagnostic follow-up.
New CDC guidance and fresh research reinforce the same core message: long COVID can follow even a mild infection, normal tests do not rule it out, and the best proven way to lower risk is still reducing the chances of severe COVID-19. Early studies on fatigue treatments and supplements are interesting, but they are not yet practice-changing. New U.S. data also suggest long COVID still falls unevenly across communities, which matters for access to diagnosis and care.
The FDA says it wants to make room for individualized treatments in ultra-rare diseases without lowering the bar for evidence. A new draft framework, plus several 2026 approvals, shows how regulators are trying to balance flexibility with proof that a therapy targets the disease’s root cause.
The FDA has finalized new guidance on collecting pregnancy-safety data after a drug or biologic is approved. The change will not rewrite labels overnight, but it could strengthen the evidence doctors and patients rely on when deciding whether medicine is needed during pregnancy.
New 2026 research adds momentum to earlier LDL lowering for people without prior heart attack or stroke. But the basics have not changed: healthy habits, blood pressure control, cholesterol screening, and statins remain the mainstay for most primary prevention decisions.
A large randomized trial suggests breast cancer screening can be tailored by risk without missing more advanced cancers compared with standard screening. But U.S. guidance has not broadly shifted yet, and experts still see important limits in the evidence.
The FDA is testing a faster way to view some trial data as studies are running while also pressing sponsors to catch up on overdue results reports. The big takeaway for readers: this is a change in transparency and timing, not proof that a therapy works.
The FDA has finalized guidance meant to help sponsors collect better pregnancy safety data after a drug or biologic is approved. The goal is not to label any one medicine safer or riskier on its own, but to improve the evidence doctors and patients can use later.
The FDA has finalized guidance meant to help drug and biologic makers study pregnancy safety after a product is approved. For patients, the practical message is simple: this does not change prescriptions by itself, and it does not prove a medicine is safe or unsafe in pregnancy.
CDC’s updated Long COVID guidance keeps the focus on symptoms, function, and follow-up care. The key takeaway for readers is simple: a normal lab workup does not automatically rule out Long COVID.
A new FDA-approved treatment for Menkes disease raises the stakes for early diagnosis. The hard part now is whether newborn screening systems can find ultra-rare disorders fast enough, accurately enough, and fairly enough to help babies in time.
CDC’s latest coverage dashboard shows that many pregnant people still have not chosen an RSV prevention strategy. The practical question is still timing: maternal Abrysvo in late pregnancy or infant nirsevimab after birth.
A new 2026 review is putting more attention on blood pressure checks done at home and other settings outside the doctor’s office. Those readings can sometimes spot masked high blood pressure or rule out a one-time office spike, which may help prevention efforts. The takeaway is practical: home monitoring can add useful information, but it works best with the right device, proper technique, and follow-up with a clinician.
A recent hypertension guidance update puts more emphasis on accurate blood-pressure measurement, repeated confirmation, home monitoring, and risk-based prevention. For many adults, the practical takeaway is not a new alarm bell, but a clearer plan for when lifestyle steps, follow-up, and medication may come into play.
The CDC has added a new screening page that brings a once mostly specialist idea into a more public-facing conversation: type 1 diabetes can begin before symptoms, and some people at higher risk may be identified earlier with a blood test. That matters because many people still learn they have type 1 diabetes only after a medical emergency such as diabetic ketoacidosis.
A new NIH-backed clinical trial suggests the answer may be yes. In federally qualified health centers, a care model built around home monitoring, coaching, and faster medication adjustments lowered blood pressure more than enhanced usual care over 18 months — but it is a care strategy, not a new drug, and questions remain about cost, scale, and long-term outcomes.
The CDC updated its Long COVID clinical guidance on March 9, 2026, with a practical message for patients and clinicians: persistent symptoms can be evaluated even when routine tests look normal. The agency says care should focus on the person’s history, exam, symptoms, and function—not on waiting for one test to “prove” Long COVID.
CDC’s March 2026 updates reinforce a cautious message: Long COVID is real, testing is still imperfect, and treatment evidence remains limited. New research adds clues about symptoms and possible risks, but it does not yet point to a single proven fix.
A COVID booster may still lower the chance of long COVID, but it is not a guarantee. The latest CDC guidance says vaccination remains the best available tool to prevent long COVID, while newer studies suggest protection that is real but not complete.
End of content
End of content
